Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
13 août 2024 16h05 HE
|
Alumis Inc.
– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis – – Initiated Phase 1 clinical trial for A-005 in healthy participants – – Completed IPO...
Mindera Health Announces Appointment of Kamal Adawi as Chief Financial Officer
12 août 2024 08h00 HE
|
Mindera Health
San Diego, CA, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Ron Rocca, President and CEO of Mindera Health, said, “We’re very pleased to add Kamal to the executive team. I am thrilled to work with Kamal again...
[Latest] Global Medical Aesthetics Market Size/Share Worth USD 36,168.8 Million by 2033 at a 8.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
06 août 2024 03h30 HE
|
Custom Market Insights
Austin, TX, USA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Medical Aesthetics Market Size, Trends and Insights By Product Type (Aesthetic...
Mindera Health Secures $14 Million to Advance Commercialization of First and Only Psoriasis Precision Medicine Test
31 juil. 2024 08h00 HE
|
Mindera Health
San Diego, CA, July 31, 2024 (GLOBE NEWSWIRE) -- Mindera Health Inc. announces the closing of a $14M convertible note financing, led by Mountain Group Partners and other existing investors in...
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
29 juil. 2024 08h00 HE
|
Alumis Inc.
Alumis announced that patient dosing has commenced in the ONWARD Phase 3 clinical program for ESK-001 for the treatment of psoriasis.
$6.97 Billion Photodynamic Therapy Market Outlook, 2024-2032, Featuring Detailed Analysis of Gladerma, Sun Pharmaceutical Industries, Biofrontera, Lumibird, Bausch Health Companies, and More
06 juin 2024 04h22 HE
|
Research and Markets
Dublin, June 06, 2024 (GLOBE NEWSWIRE) -- The "Photodynamic Therapy Market Report by Product Types, Application, End-user, Countries and Company Analysis 2024-2032" report has been added to ...
Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
05 juin 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that five abstracts will be presented at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago June 8-10.
Dermatology Collaboration and Licensing Deals Report, 2016 to 2024, Featuring 600+ Companies and 400+ Deals
02 mai 2024 07h33 HE
|
Research and Markets
Dublin, May 02, 2024 (GLOBE NEWSWIRE) -- The "Dermatology Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Dermatology Collaboration and...
ROSEN, A TOP RANKED LAW FIRM, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VTYX
08 avr. 2024 16h48 HE
|
The Rosen Law Firm PA
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i) pursuant...
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
01 avr. 2024 07h00 HE
|
Sol-Gel Technologies Ltd.
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream